Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Fda Inspections
  6. /
  7. Boehringer Ingelheim Fremont, Inc.
FDA Inspection
•Boehringer Ingelheim Fremont, Inc.•February 25, 2010

Boehringer Ingelheim Fremont, Inc. – FDA Inspection, Feb 25, 2010

Record Details

This FDA Inspection record concerns Boehringer Ingelheim Fremont, Inc., with an inspection on February 25, 2010, issued by the Center for Drug Evaluation and Research, covering drugs.

Company
Boehringer Ingelheim Fremont, Inc.
Inspection Date
February 25, 2010
Product Type
Drugs
Office
Center for Drug Evaluation and Research
View Company Profile

ID · b12233de-a157-49d1-9735-de1d79f08060

Inspection Facts

Voluntary Action Indicated (VAI)

Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.

Inspection number
653544
FDA center
Human Drugs
Project area
Drug Quality Assurance

FDA Citations

12
  1. 21 CFR 211.46(c)Exhaust systems inadequate to control air contamination
  2. 21 CFR 211.188Prepared for each batch, include complete information
  3. 21 CFR 211.84(a)Components withheld from use pending release
  4. 21 CFR 211.46(b)Equipment for Environmental Control
  5. 21 CFR 211.63Equipment Design, Size and Location
  6. 21 CFR 211.160(b)Scientifically sound laboratory controls
  7. 21 CFR 211.113(b)Validation lacking for sterile drug products
  8. 21 CFR 211.192Investigations of discrepancies, failures
  9. 21 CFR 211.22(d)Procedures not in writing, fully followed
  10. 21 CFR 211.56(c)Written procedures lacking for use of pesticides etc.

Showing 10 of 12 citations.

Full citation text and observation details available on the Dashboard.

Other FDA inspections of Boehringer Ingelheim Fremont, Inc.

7
DateClassificationOfficeProject area
May 16, 2024Not classifiedSan Francisco District Office
April 13, 2023Not classifiedSan Francisco District Office
November 4, 2022VAICenter for Drug Evaluation and ResearchDrug Quality Assurance
August 24, 2018VAICenter for Drug Evaluation and ResearchDrug Quality Assurance
April 4, 2017Not classifiedSan Francisco District Office
View all 7 other inspections on the company page
Other documents for Boehringer Ingelheim Fremont, Inc.
  • FDA Inspection 1263388 - 2024-05-16
  • FDA Inspection 1205076 - 2023-04-13
  • FDA Inspection 1187410 - 2022-11-04
  • FDA Inspection 1063730 - 2018-08-24
  • FDA Inspection 1005958 - 2017-04-04

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Boehringer Ingelheim Fremont, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.